Dr. Ali Al-Ghamrawy, Chairman of the EDA, held a meeting with representatives from Utopia Pharmaceuticals, headed by Dr. Al-Saeed Kamel Mohamed, Chairman of the company's Board of Directors. This meeting aligns with the Authority’s commitment to strengthening partnerships with pharmaceutical companies operating in the Egyptian market and supporting efforts to develop and grow the national pharmaceutical industry.
Utopia Pharmaceuticals presented its current activities and future expansion strategies. The company emphasized its keenness to keep pace with rapid developments in the pharmaceutical industry and its ongoing efforts to enhance production and manufacturing capabilities in accordance with the latest international standards, thereby supporting Egypt's healthcare ecosystem.
The meeting addressed several technical and regulatory files of mutual interest, including procedures for the registration of pharmaceutical products, and discussed ways to accelerate regulatory procedures while maintaining full commitment to all standards of quality, efficacy, and safety.
Mechanisms to support innovation in the pharmaceutical industry and to enhance reliance on local manufacturing were also discussed during the meeting, contributing to pharmaceutical product security. Also, the discussion covered supporting state plans to increase pharmaceutical exports and opening new markets for Egyptian products.
The EDA reaffirmed its commitment to applying the highest internationally recognized regulatory standards to ensure the safety, quality, and efficacy of marketed pharmaceutical products. The Authority stressed the importance of companies adhering to all technical and regulatory requirements, considering this the cornerstone of enhancing citizen confidence in the pharmaceutical system.
Dr. Al-Ghamrawy emphasized the Authority's keenness to maintain continuous communication with industry partners, listen to the challenges they face, and work to overcome them transparently to balance investment encouragement with the protection of public health.
He noted that the EDA continues to evolve its regulatory framework in line with global best practices to enhance the competitiveness of the Egyptian pharmaceutical sector regionally and internationally.
Representatives of Utopia Pharmaceuticals expressed their appreciation for the EDA’s role in supporting and developing the industry, affirming their commitment to continue fruitful cooperation with the Authority during the coming period to achieve common goals.
This meeting reflects the EDA’s strategy aimed at achieving integration with industry partners and creating a regulatory environment supportive of investment. This contributes to ensuring the availability of high-quality pharmaceutical products that meet the needs of the Egyptian market, alongside supporting export plans to regional and global markets.